Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.

[1][2] Icrucumab was developed by ImClone Systems Inc.

It is undergoing Phase I trials.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.